ADAR1 Capital Management »

Arcutis Biotherapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Arcutis Biotherapeutics (ARQT) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Arcutis Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Arcutis Biotherapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arcutis Biotherapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $42k 4.3k 9.91
2023-12-31 $888k 275k 3.23

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Arcutis Biotherapeutics

Jennison Associates
Rubric Capital Management
Suvretta Capital Management
BlackRock
Frazier Life Sciences Management
BlackRock
Vanguard Group
State Street Corporation
Franklin Resources
Morgan Stanley
Citadel Advisors
Cormorant Asset Management
Geode Capital Management
Ensign Peak Advisors
Pivotal bioVenture Partners Investment Advisor

View all funds holding Arcutis Biotherapeutics